Fundraising Fox
Inceptor Bio
Morrisville, US · Founded 2020 · North Carolina LLC · 20 employees on LinkedIn · 1 known investors
Find your way into Inceptor Bio
Sign up to see every warm intro you have to Inceptor Bio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Inceptor Bio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Inceptor Bio is a clinical-stage biotechnology company developing cell therapies for cancer, focused on solid tumors. Its OUTLAST platform reprograms T cells during manufacturing to withstand the tumor microenvironment, and its lead candidate is IB-T101.
Founders & leadership
JL
Jason LawrenceVice President Finance2021–2026Jason Lawrence is Executive Officer at Inceptor Bio, a clinical-stage biotechnology company developing cell therapies for solid tumors. He brings experience in financial leadership for biotech and life sciences companies, with expertise in capital raises, M&A, financial planning and analysis, SEC reporting, and operational functions including HR, IT, and supply chain.
MS
Matthias SchroffChief Executive OfficerExecutive officer and director at Inceptor Bio, a clinical-stage cell therapy company developing treatments for solid tumors. Schroff has over 17 years of experience in biotechnology leadership across immuno-oncology, including roles developing capabilities in manufacturing and clinical advancement.
AS
Abraham S. MaingiExecutive
SM
DM
David Michael JohnstonNamed on SEC filing
Board
MB
ES
Elizabeth SmithBoard director
MG
Mark GilbertBoard directorStrategic Advisor at Kineticos Life Sciences
Investors · 1
Also in the syndicate · 1
Kineticos Ventureslead
Reported raises · per SEC filings
Form D private placements$65.7M disclosed across 5 rounds · 2020–2025
▶$3.3MraisedJan 2025 · 10 investors · BiotechnologyRule 506(b)
▶$3.3MraisedJan 2025 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Abraham S. MaingiExecutive Officer
- Elizabeth SmithDirector
- Jason LawrenceExecutive Officer
- Derek HenneckeDirector
- Matthias SchroffExecutive Officer, Director
- Shailesh MaingiDirector
- George FotiadesDirector
- Mark GilbertDirector
- Offering amount
- $3.4M
- Amount sold
- $3.3M
- First sale
- Jan 2025
- Incorporated
- Limited Liability Company, North Carolina, 2020
- Federal exemptions
- 06b
▶$15.9MraisedJul 2024 · 13 investors · BiotechnologyRule 506(b)
▶$15.9MraisedJul 2024 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Elizabeth SmithDirector
- Shailesh MaingiDirector
- George FotiadesDirector
- Derek HenneckeDirector
- Mark GilbertDirector
- Jason LawrenceExecutive Officer
- Matthias SchroffExecutive Officer, Director
- Abraham S. MaingiExecutive Officer
- Offering amount
- $15.9M
- Amount sold
- $15.9M
- First sale
- Oct 2022
- Incorporated
- Limited Liability Company, North Carolina, 2020
- Federal exemptions
- 06b
▶$37.7MraisedMar 2022 · 9 investors · BiotechnologyRule 506(b)
▶$37.7MraisedMar 2022 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David Michael JohnstonDirector
- Shailesh MaingiExecutive Officer, Director, Promoter
- Mark BamforthDirector
- Jason LawrenceExecutive Officer
- Matthew John HainesExecutive Officer
- Derek HenneckeDirector
- Abraham Surinder MaingiExecutive Officer, Director
- Michael NicholsonExecutive Officer
- Offering amount
- $60.8M
- Amount sold
- $37.7M
- First sale
- Feb 2022
- Incorporated
- Limited Liability Company, North Carolina, 2020
- Federal exemptions
- 06b
▶$5.5MraisedJul 2021 · 20 investors · BiotechnologyRule 506(b)
▶$5.5MraisedJul 2021 · 20 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David Michael JohnstonDirector
- Abraham Surinder MaingiExecutive Officer, Director
- Shailesh MaingiExecutive Officer, Director, Promoter
- Mark BamforthDirector
- Derek HenneckeDirector
- Offering amount
- $18.1M
- Amount sold
- $5.5M
- First sale
- Jul 2021
- Incorporated
- Limited Liability Company, North Carolina, 2020
- Federal exemptions
- 06b, 3C, 3C.1
▶$3.3MraisedSep 2020 · 6 investors · BiotechnologyRule 506(b)
▶$3.3MraisedSep 2020 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Abraham Surinder MaingiExecutive Officer, Director
- Shailesh MaingiPromoter
- Offering amount
- $3.3M
- Amount sold
- $3.3M
- First sale
- Apr 2020
- Incorporated
- Limited Liability Company, North Carolina, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Inceptor Bio went on to found or lead other companies.
Related companies · 1
Companies working in the same space as Inceptor Bio.
In the news
Frequently asked questions
- What does Inceptor Bio do?
- Inceptor Bio is a clinical-stage biotechnology company developing cell therapies for cancer, focused on solid tumors. Its OUTLAST platform reprograms T cells during manufacturing to withstand the tumor microenvironment, and its lead candidate is IB-T101.
- How much funding has Inceptor Bio raised?
- Inceptor Bio has disclosed $65.7M raised across 5 rounds.
- Where is Inceptor Bio headquartered?
- Inceptor Bio is headquartered in Morrisville, US.